Kpc Pharmaceuticals Inc(600422) 3 the annual report of 2021 was released on the evening of March 18. The company achieved an operating revenue of 8.254 billion yuan in 2021, an increase of 6.95% year-on-year; The net profit attributable to the shareholders of the listed company was 508 million yuan, a year-on-year increase of 11.12%; The basic earnings per share is 0.67 yuan. The company plans to distribute a cash dividend of 2.7 yuan (including tax) to all shareholders for every 10 shares.
For the growth of operating revenue in 2021, the company said that it was mainly due to the multi-channel layout, focusing on expanding the off-site market, and the increase of sales revenue of the pharmaceutical industry.
According to the annual report, in 2021, based on the advantageous treatment field, the company focused on core resources and accelerated the business layout of kunyao Xuesaitong oral series products with kunyao Xuesaitong Soft Capsule as the core and “Kun traditional Chinese medicine 1381” high-quality national medicine series products with Shenling jianpiwei granule and Shugan granule as the core in the off-site market. Driven by the multi-dimensional resonance of large categories, strong brands and channel expansion, the company’s oral product business and out of hospital business continued to achieve rapid growth, and brought continuous breakthrough changes to the company’s product structure revenue and channel structure revenue.
In the business plan, Kpc Pharmaceuticals Inc(600422) said that in 2022, the company will comply with the industrial reform, anchor the development orientation of “becoming the top 10 of Chinese brand traditional Chinese medicine in three years”, accelerate the integration of marketing team and middle and back office, accelerate the implementation of digital transformation and upgrading, deeply cultivate the company’s core competitiveness in the field of botanical medicine and high-quality national medicine, and build a multi brand, multi category, multi pipeline and omni-channel brand group of traditional Chinese medicine. On the one hand, taking the series of oral products of Kunming medicine Xuesaitong and the series of high-quality national medicine products of “Kunming traditional Chinese medicine 1381” as the “two sharp knives” for the implementation of strategic breakthrough, we will strengthen the path of oral, retail and branding, and create a new profit growth pole for the long-term and steady development of the company’s performance. On the other hand, the company always adheres to patient-centered, firm R & D and innovation; Focus on core advantages and characteristic fields, actively layout R & D and innovation through multiple channels, enrich product pipelines, and continuously improve the company’s core competitive advantages. At the same time, comprehensively promote digital construction.
